Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchHydrogen PeroxideHydrogen Per.. (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Antiseptic Mouthwash /​ Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) (AMPoL)

Gansky et al., NCT04409873, AMPoL, NCT04409873, Nov 2023
https://c19early.org/gansky.html
Recovery 67% Improvement Relative Risk Hydrogen Peroxide  AMPoL  EARLY TREATMENT  DB RCT Is early treatment with hydrogen peroxide beneficial for COVID-19? Double-blind RCT 54 patients in the USA Trial underpowered to detect differences c19early.org Gansky et al., NCT04409873, November 2023 Favorshydrogen peroxide Favorscontrol 0 0.5 1 1.5 2+
24th treatment shown to reduce risk in May 2021, now with p = 0.024 from 8 studies.
Lower risk for viral clearance.
No treatment is 100% effective. Protocols combine treatments.
5,900+ studies for 172 treatments. c19early.org
Early terminated RCT with very limited information reported in the registry and only one patient showing symptoms. There is not enough information to assess the viral load results in the registry - the protocol indicates right-censoring for patients with undetectable viral load which may be the majority of patients at 4 weeks.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Study covers hydrogen peroxide and cetylpyridinium chloride.
risk of no recovery, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 6 (0.0%), control 1 of 6 (16.7%), NNT 6.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gansky et al., 18 Nov 2023, Double Blind Randomized Controlled Trial, USA, preprint, 1 author, trial NCT04409873 (history) (AMPoL). Contact: stuart.gansky@ucsf.edu, sepideh.banava@ucsf.edu.
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit